Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma

Breast Cancer Research and Treatment
F JournéG Laurent

Abstract

IBEP-2, an established cell line recently derived from breast carcinoma, was characterized with regard to estrogen receptor (ER) expression, cell mitogenic response to estrogenic stimulation and sensitivity to antiestrogens. In addition, we examined ER modulation following binding of agonist and antagonists, and the ER-mediated induction of progesterone receptor (PgR). ER level in IBEP-2 cells, determined by enzyme-linked immunoassay (EIA), was slightly higher than that measured in MCF-7 cells (662 v.s. 595 fmol/mg protein). When tested on IBEP-2 and MCF-7, various agonists stimulated cell growth with EC50's reflecting different estrogenic potencies (E(2) approximately diethylstilbestrol > E(1) > genistein). IBEP-2 appeared slightly more sensitive than MCF-7, especially to E(2) (at least 4-fold difference between EC50 values). By contrast, IBEP-2 and MCF-7 were equally sensitive to the growth inhibitory effect of antiestrogens 4-hydroxy-tamoxifen (OH-Tam) and ICI 182,780. As revealed by immunoblotting and immunofluorescence using anti-ER alpha antibodies, ER expression in IBEP-2 cells was modulated by E(2) and estrogen antagonists like it has been shown in other ER-positive cell lines, that is, E(2) and ICI 182,780 caused ER do...Continue Reading

References

May 1, 1979·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I KeydarH J Brenner
Dec 1, 1988·Journal of Cutaneous Pathology·F O'ValleT Alvaro
Oct 1, 1985·Analytical Biochemistry·P K SmithD C Klenk
Nov 1, 1973·Journal of the National Cancer Institute·H D SouleM Brennan
Sep 1, 1974·Journal of the National Cancer Institute·R CailleauW J Reeves
Jun 4, 1998·International Journal of Cancer. Journal International Du Cancer·B SiwekJ J Body
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·Z NawazB W O'Malley
Apr 27, 1999·FEBS Letters·A El Khissiin, G Leclercq
Oct 12, 1999·Endocrine-related Cancer·S Green, B Furr
Oct 21, 1999·The Journal of Steroid Biochemistry and Molecular Biology·M D DavisS C Brooks
Dec 1, 1999·Endocrinology·A L WijayaratneD P McDonnell
Feb 2, 2000·Journal of Cellular Biochemistry·A StoicaM B Martin
Feb 3, 2000·Proceedings of the National Academy of Sciences of the United States of America·C A LangeK B Horwitz
Jul 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·A DaceS Cheng
Feb 13, 2001·The Journal of Steroid Biochemistry and Molecular Biology·J A Gustafsson, M Warner
Feb 22, 2001·Annual Review of Physiology·K Pettersson, J A Gustafsson
Apr 20, 2001·Maturitas·B S Hulka, P G Moorman
Jun 23, 2001·Molecular and Cellular Endocrinology·O M ConneelyF J De Mayo
Nov 22, 2001·The Journal of Biological Chemistry·Jennifer K RicherKathryn B Horwitz
Dec 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·E V JensenJ A Gustafsson
Feb 19, 2002·The Journal of Steroid Biochemistry and Molecular Biology·F LabrieG Tremblay
Mar 8, 2002·American Journal of Physiology. Endocrinology and Metabolism·Mara T Preisler-MashekElaine T Alarid
Mar 21, 2002·The Lancet Oncology·T J KeyE Banks
Apr 12, 2002·The Journal of Steroid Biochemistry and Molecular Biology·Annika VienonenTimo Ylikomi
May 22, 2002·The Journal of Biological Chemistry·Britta M JacobsenKathryn B Horwitz

❮ Previous
Next ❯

Citations

Nov 6, 2007·Biochimica Et Biophysica Acta·Anne E Doyle, James D Yager
Jun 1, 2004·The Journal of Biological Chemistry·Sandip K MishraRakesh Kumar
Aug 10, 2019·Experimental Cell Research·Maddaly RaviAastha Joshipura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.